Cargando…

TIGIT/CD226 Axis Regulates Anti-Tumor Immunity

Tumors escape immune surveillance by inducing various immunosuppressive pathways, including the activation of inhibitory receptors on tumor-infiltrating T cells. While monoclonal antibodies (mAbs) blocking programmed cell death 1 (PD-1), programmed death-ligand 1 (PD-L1), and cytotoxic T lymphocyte-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yeo, Jinah, Ko, Minkyung, Lee, Dong-Hee, Park, Yoon, Jin, Hyung-seung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7997242/ https://www.ncbi.nlm.nih.gov/pubmed/33670993 http://dx.doi.org/10.3390/ph14030200

Ejemplares similares

Hitting the complexity of the TIGIT-CD96-CD112R-CD226 axis for next-generation cancer immunotherapy
por: Jin, Hyung-seung, et al.
Publicado: (2021)

TIGIT-CD226-PVR axis: advancing immune checkpoint blockade for cancer immunotherapy
por: Chiang, Eugene Y, et al.
Publicado: (2022)

Imbalance of the CD226/TIGIT Immune Checkpoint Is Involved in the Pathogenesis of Primary Biliary Cholangitis
por: Deng, Chuiwen, et al.
Publicado: (2020)

CD226 and TIGIT Cooperate in the Differentiation and Maturation of Human Tfh Cells
por: Yasutomi, Motoko, et al.
Publicado: (2022)

The CD226/TIGIT axis is involved in T cell hypo-responsiveness appearance in long-term kidney transplant recipients
por: Del Bello, Arnaud, et al.
Publicado: (2022)

Examination of the TIGIT-CD226-CD112-CD155 Immune Checkpoint Network during a Healthy Pregnancy
por: Meggyes, Matyas, et al.
Publicado: (2022)

Perturbed CD8(+) T cell TIGIT/CD226/PVR axis despite early initiation of antiretroviral treatment in HIV infected individuals
por: Tauriainen, Johanna, et al.
Publicado: (2017)

Expansion of circulating peripheral TIGIT+CD226+ CD4 T cells with enhanced effector functions in dermatomyositis
por: Li, Wenli, et al.
Publicado: (2021)

TIGIT can inhibit T cell activation via ligation-induced nanoclusters, independent of CD226 co-stimulation
por: Worboys, Jonathan D., et al.
Publicado: (2023)

Examination of the TIGIT, CD226, CD112, and CD155 Immune Checkpoint Molecules in Peripheral Blood Mononuclear Cells in Women Diagnosed with Early-Onset Preeclampsia
por: Szereday, Laszlo, et al.
Publicado: (2021)

Helios but not CD226, TIGIT and Foxp3 is a Potential Marker for CD4(+) Treg Cells in Patients with Rheumatoid Arthritis
por: Yang, Mengru, et al.
Publicado: (2019)

Emergence of the CD226 Axis in Cancer Immunotherapy
por: Conner, Michael, et al.
Publicado: (2022)

Expression of the Inhibitory Receptor TIGIT Is Up-Regulated Specifically on NK Cells With CD226 Activating Receptor From HIV-Infected Individuals
por: Yin, Xiaowan, et al.
Publicado: (2018)

Tumor FAK orchestrates immunosuppression in ovarian cancer via the CD155/TIGIT axis
por: Ozmadenci, Duygu, et al.
Publicado: (2022)

Targeting the “PVR–TIGIT axis” with immune checkpoint therapies
por: Gorvel, Laurent, et al.
Publicado: (2020)

TIGIT/CD155 axis mediates resistance to immunotherapy in patients with melanoma with the inflamed tumor microenvironment
por: Kawashima, Shusuke, et al.
Publicado: (2021)

The Ratio of CD226 and TIGIT Expression in Tfh and PD-1(+)ICOS(+)Tfh Cells Are Potential Biomarkers for Chronic Antibody-Mediated Rejection in Kidney Transplantation
por: Fan, Ji-wen, et al.
Publicado: (2022)

Defining the Immune Checkpoint Landscape in Human Colorectal Cancer Highlights the Relevance of the TIGIT/CD155 Axis for Optimizing Immunotherapy
por: Ducoin, Kathleen, et al.
Publicado: (2022)

TIGIT and PD-1 Immune Checkpoint Pathways Are Associated With Patient Outcome and Anti-Tumor Immunity in Glioblastoma
por: Raphael, Itay, et al.
Publicado: (2021)

Anti-TIGIT therapies for solid tumors: a systematic review
por: Rousseau, A., et al.
Publicado: (2023)

Upregulation of the CD155-CD226 Axis Is Associated With Muscle Inflammation and Disease Severity in Idiopathic Inflammatory Myopathies
por: Li, Wenli, et al.
Publicado: (2023)

TIGIT Can Exert Immunosuppressive Effects on CD8(+) T Cells by the CD155/TIGIT Signaling Pathway for Hepatocellular Carcinoma In Vitro
por: Zhang, Changkun, et al.
Publicado: (2020)

Enhancing T cell anti-tumor efficacy with a PD1-TIGIT chimeric immune-checkpoint switch receptor
por: Zhao, Jingjing, et al.
Publicado: (2023)

CD226: An Emerging Role in Immunologic Diseases
por: Huang, Zhiyi, et al.
Publicado: (2020)

Implication of TIGIT(+) human memory B cells in immune regulation
por: Hasan, Md Mahmudul, et al.
Publicado: (2021)

Correlation of the TIGIT-PVR immune checkpoint axis with clinicopathological features in triple-negative breast cancer
por: Boissière-Michot, Florence, et al.
Publicado: (2022)

Mechanisms of TIGIT-driven immune suppression in cancer
por: Kurtulus, Sema, et al.
Publicado: (2014)

Expression of the immune checkpoint receptor TIGIT in seminoma
por: Hinsch, Andrea, et al.
Publicado: (2019)

Update in TIGIT Immune-Checkpoint Role in Cancer
por: Annese, Tiziana, et al.
Publicado: (2022)

Overexpression of TIGIT in NK and T Cells Contributes to Tumor Immune Escape in Myelodysplastic Syndromes
por: Meng, Fanqiao, et al.
Publicado: (2020)

Increased levels of soluble CD226 in sera accompanied by decreased membrane CD226 expression on peripheral blood mononuclear cells from cancer patients
por: Xu, Zhuwei, et al.
Publicado: (2009)

TIGIT blockade repolarizes AML-associated TIGIT(+) M2 macrophages to an M1 phenotype and increases CD47-mediated phagocytosis
por: Brauneck, Franziska, et al.
Publicado: (2022)

Expression of CD226 is associated to but not required for NK cell education
por: Wagner, Arnika K., et al.
Publicado: (2017)

Expression of the immune checkpoint receptor TIGIT in Hodgkin’s lymphoma
por: Li, Wenchao, et al.
Publicado: (2018)

TIGIT limits immune pathology during viral infections
por: Schorer, Michelle, et al.
Publicado: (2020)

TIGIT, a novel immune checkpoint therapy for melanoma
por: Tang, Wei, et al.
Publicado: (2023)

TIGIT in cancer immunotherapy
por: Chauvin, Joe-Marc, et al.
Publicado: (2020)

Use of aspirin in the prevention of colorectal cancer through TIGIT‐CD155 pathway
por: Ma, Bin, et al.
Publicado: (2019)

Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8(+) T cell responses
por: Banta, Karl L., et al.
Publicado: (2022)

TIGIT-related transcriptome profile and its association with tumor immune microenvironment in breast cancer
por: Zhang, Qin, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_g7c33dgf2s1dhag4j1d5kjmt65